MRC1 and carcinoma: Considering this overlap of MMR and HRR and with the advent of drugs targeting DNA repair in clinical practice for other cancer entities, especially PARP-inhibitors for BRCA-mutated carcinomas (26, 27), we proposed that our subgroup with a dysregulated MMR immunophenotype may be also a suitable cohort to search for additional defects in DNA repair processes.